Australia's #1 directory for medical equipment & suppliers

Left Atrial Appendage Closure Device - WATCHMAN

Supplier: Life Systems Medical

The WATCHMAN Left Atrial Appendage Closure Technology is a device based solution designed to be permanently implanted at or slightly distal to the ostium (opening) of the left atrial appendage (LAA) to trap blood clots before they exit the LAA.


The WATCHMAN LAA Closure Technology is a three part system consisting of a transseptal access sheath, a delivery catheter and an implantable device.

WATCHMAN LAA Closure Device

The WATCHMAN Device is a self-expanding nitinol frame structure with fixation barbs and a permeable polyester fabric that covers the atrial facing surface of the device.

The device is preloaded within a delivery catheter. The WATCHMAN Device is available in 5 sizes to accommodate the unique anatomy of each patient's LAA.

WATCHMAN Access Sheath

The WATCHMAN Access Sheath is utilized to gain access into the LAA and serves as a conduit for the delivery catheter.

The Access Sheath is available in both a single curve (90 degree angle) and double curve distal tip configuration.

LAA Closure Procedure

The WATCHMAN LAA Closure Device placement procedure may be done under local or general anesthesia in a catheterization laboratory setting using a standard transseptal technique.

The procedure usually lasts about an hour and the patient is typically in the hospital for 24 hours following the procedure.

A transesophageal echocardiogram (TEE) is performed to measure the LAA to determine which size WATCHMAN Device to be implanted.

After the inter-atrial septum is crossed using a standard transseptal access system, the WATCHMAN Access Sheath and Dilator are advanced over a guidewire into the left atrium.

The Access Sheath is then carefully advanced into the distal portion of the LAA over a pigtail catheter.

The WATCHMAN Delivery System is prepped, inserted into the Access Sheath, and slowly advanced under fluoroscopic guidance.

The WATCHMAN Device is then deployed into the LAA. The device release criteria are confirmed via fluoroscopy and TEE prior to releasing the Device.